In the GeparNuevo trial, PD-L1 expression was evaluated using the Ventana SP263 antibody (Ventana Medical Systems Inc., Tucson, AZ) and was defined as the proportion of tumour cells with membranous staining (PD-L1-TC) and proportion of TILs with membranous or cytoplasmic staining (PD-L1-IC) [20]. This evidence concerns the gene CD274 and neoplasm.